Announcement on the Change of Certain Special Accounts for Raised Funds
Shandong Keyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
On May 29, 2026, the Company held the 23rd meeting of the 4th Board of Directors, where it reviewed and approved the proposal on changing certain special accounts for raised funds. The Company agreed to open new special accounts for raised funds at the Jinan Branch of Shanghai Pudong Development Bank and the Dongying Branch of Yantai Bank, transferring the principal and interest balance of the raised funds currently held at the Jinan Licheng Branch of China Postal Savings Bank (specific amount to be determined on the transfer date) to the new special accounts. After the change is completed, the Company will cancel the original special accounts for raised funds, and the corresponding "Tripartite Supervision Agreement for Raised Funds" will become invalid. The Company will re-sign the "Tripartite Supervision Agreement for Raised Funds." The specific situation is as follows:
1. Basic Situation of Raised Funds
With the approval of the China Securities Regulatory Commission regarding the registration of Shandong Keyuan Pharmaceutical Co., Ltd.'s initial public offering (Approval No. [2023] 362), and with the consent of the Shenzhen Stock Exchange, the Company publicly issued 19,350,000 ordinary shares (A shares) at a par value of RMB 1 per share, with an issue price of RMB 44.18 per share, raising a total of RMB 854,883,000.00. After deducting issuance costs of RMB 89,961,225.68, the net amount raised is RMB 764,921,774.32. The status of the raised funds has been verified by Xinyong Zhonghe Accounting Firm (Special General Partnership), which issued Verification Report No. XYZH/2023JNAA5B0068 on March 30, 2023.